Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 23;41:75. doi: 10.1186/s13046-022-02284-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Cisplatin+MLN4924 combination induces cell cycle alteration, DNA damage and senescence. Primary MPM cells derived from 3 different histopathological subtypes, epithelioid (EPI BAP1⁺ UPN7 and EPI BAP1^- UPN11), biphasic (BIP BAP1⁺ UPN14 and BIP BAP1^- UPN16) and sarcomatous (SAR BAP1⁺ UPN22 and SAR BAP^- UPN23) were incubated in fresh medium (CTRL), with 50 μM cisplatin (PT), 0.2 μM MLN4924 (MLN) or their combination (PT+MLN). A. Cell cycle distribution was measured by flow cytometry in duplicates, after 24 h (upper panels) or 48 h (lower panels). Data are presented as means of 2 primary MPM for each histopathological subtype used + SD (n = 3). *p<0.05, **p<0.01, ***p < 0.001: treated cells vs CTRL cells; °p<0.05, °°p < 0.01: PT+MLN-treated cells vs PT-treated cells. B. DNA damage was measured fluorometrically after 24 h. Data are presented as means of 2 primary MPM for each histopathological subtype used+ SD (n = 3). ***p < 0.001: treated cells vs CTRL cells; °p < 0.05, °°°p < 0.001: PT+MLN-treated cells vs PT -treated cells. C. Left panel: representative sections of AB1 tumors from each group of animals, treated as indicated in Figure 1D-E, stained with the Ki67 antibody. Nuclei were counter-stained with hematoxylin. Scale bar: 100 μm (10x ocular; 40x objective). At least 10 fields were examined for each condition. Right panel: quantification of Ki67-positive cells versus the total number of cells, performed with the ImageJ software. Data are presented as means + SD. *p<0.05, **p<0.01, ***p < 0.001: treated cells vs CTRL cells; °°°p < 0.001: PT+MLN-treated cells vs PT-treated cells. D. Left panel: representative TUNEL staining on tumors sections from each group of animals, as above. Nuclei were counter-stained with DAPI. Scale bar: 200 μm. (10x ocular, 40x objective). At least 10 fields were examined for each condition. Right panel: quantification of TUNEL-positive cells versus the total number of cells, performed with the ImageJ software. Data are presented as means + SD. ***p < 0.001: treated cells vs CTRL cells; °°°p < 0.001: PT+MLN-treated cells vs PT-treated cells